Turnstone Biologics Corp. (TSBX)

$0.45

-0.02

(-3.92%)

Market is closed - opens 7 PM, 11 Oct 2024

Performance

  • $0.44
    $0.47
    $0.45
    downward going graph

    2.38%

    Downside

    Day's Volatility :7.01%

    Upside

    4.74%

    downward going graph
  • $0.45
    $5.75
    $0.45
    downward going graph

    0.67%

    Downside

    52 Weeks Volatility :92.23%

    Upside

    92.17%

    downward going graph

Returns

PeriodTurnstone Biologics Corp.Index (Russel 2000)
3 Months
-80.32%
0.0%
6 Months
-87.09%
0.0%
1 Year
-86.35%
0.0%
3 Years
-95.71%
-20.8%

Highlights

Market Capitalization
10.7M
Book Value
$2.58
Earnings Per Share (EPS)
-3.23
Wall Street Target Price
6.58
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-66.1%
Return On Equity TTM
-134.46%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
71.1M
EBITDA
-77.8M
Diluted Eps TTM
-3.23
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.9
EPS Estimate Next Year
-2.48
EPS Estimate Current Quarter
-0.93
EPS Estimate Next Quarter
-0.81

Analyst Recommendation

Buy
    77%Buy
    22%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Turnstone Biologics Corp.(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1362.22%

Current $0.45
Target $6.58

Technicals Summary

Sell

Neutral

Buy

Turnstone Biologics Corp. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Turnstone Biologics Corp.
Turnstone Biologics Corp.
-29.06%
-87.09%
-86.35%
-95.71%
-95.71%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-10.93%
8.12%
21.23%
85.29%
239.25%
Novo Nordisk A/s
Novo Nordisk A/s
-9.85%
-6.35%
25.79%
137.8%
353.05%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
5.73%
77.74%
60.24%
32.45%
248.92%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.6%
17.7%
29.79%
160.59%
174.92%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Turnstone Biologics Corp.
Turnstone Biologics Corp.
NA
NA
NA
-3.9
-1.34
-0.66
NA
2.58
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.81
26.81
1.38
45.04
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
39.53
39.53
1.79
3.39
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.47
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.56
0.33
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Turnstone Biologics Corp.
Turnstone Biologics Corp.
Buy
$10.7M
-95.71%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$111.6B
239.25%
26.81
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$519.8B
353.05%
39.53
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.8B
248.92%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.8B
174.92%
32.84
-4.74%

Insights on Turnstone Biologics Corp.

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 10.22M → 19.30M (in $), with an average increase of 24.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -16.45M → -21.30M (in $), with an average decrease of 13.9% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 60.2% return, outperforming this stock by 146.5%

Company Information

Organization
Turnstone Biologics Corp.
Employees
82
CEO
Dr. Sammy J. Farah M.B.A., Ph.D.
Industry
Miscellaneous

FAQs